Taken together, the presented data demonstrate that oral administration of PDE5 inhibitors selectively increases transport across brain tumor capillaries and significantly enhances the anti-tumor effect of Herceptin in mouse models of metastatic HER2/neu-positive brain tumors. Here, ERBB2 is linked to brain neoplasm.